Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®
A real announcement email from Novo Nordisk. Captured November 16, 2026.
Make this email yours
Migma AI designs one like it with your logo, colors, and images.

About this email
Captured Announcement
Novo Nordisk shares scientific research from ObesityWeek on investigational dual amylin and calcitonin receptor agonists preserving bone during weight loss.
Standard corporate press release layout featuring a top logo, bulleted highlights, multi-paragraph text with embedded data tables, and structured contact and reference lists in the footer.
Explore similar emails
Color palette
Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.